kind the for you Obi. everyone. Thank afternoon, Good remarks,
with was would INTERCEPT. not coming line been unwavering disruption deliver we employees a their to able the sincere particularly during for their ensure you worldwide to the the I and centers, much commitment to crisis, to close, of to this have top patients time blood First, express access want Without first hospitals around globe today. that to my Cerus commitment of with quarter the beginning as results sharing so we're gratitude
place sharply procedures the and of mid-March COVID-XX pandemic, result medical as blood a in sheltered in As donors and elected use product and blood postponed. were donations starting dropped
in In about primarily hear medical addition, a platelet in utilization, though started we slight procedures. essential are to platelets used decline even
was robust. by our and strong adoption demand QX showcased results, as global INTERCEPT Nevertheless, customer of
was outperformance million First exceeded quarter internal encouraging regions. sales pre-pandemic broad in with plan, the $XX.X all results of our based product and revenue
platelets see in INTERCEPT U.S. the strong We continue to demand for
QX was QX XXXX North in XXXX. revenue to up product when America XX% compared
the is previously, reduction mentioned we’ve American U.S. Cross pathogen to push to in as standard platelet respect care of As safety with a establish leading Red the the
are for and their continued ARC partnership their leadership to strong vigilance. We grateful deeply the and
make to the in In safety with efforts at increased final remains platelets. guidance North INTERCEPT an XXXX, bacterial those faster for for than rate steadfast ARC ARC to reported complying third the overall QX product sales their FDA The America. even the method on for
offer support we for plans centers of blood center previously, distributions. nationwide fairly blood five XX% five and understand marketplace late in and U.S. better largest to roundtable as big guidance February, needed. As platelet we've with leaders to senior an order resource to convened comply with from executive is discussed In the The partnership account concentrated. families over the our their
for first is similar be to major pathogen ARC the express the clearly was hear option way, the it would a that compliance. to reduction choice prove other players While leading the belief guidance encouraging
be about become continues new will hospital be standard reduction COVID may environment to of strong there belief activations the U.S. that in While a focused care near-term the in pathogen some a uncertainty
of developing action on get strategies COVID crisis. a our to environment, time is by consumed plans hospitals focused current the attention complying and we much the and In with at when guidance engaged their are
to efforts hospitals operational can with go to current is live support Given the in it pandemic, with assist and when activities their start unclear INTERCEPT. we visiting person
result, we've education users distance to increase online activation. INTERCEPT and and also them learning PR and make move to environment. with blood more are worked current tools existing accelerated hospital efforts we they and date training Furthermore, to PR aggressively sell enable XXX% remote and our training center in piloting which to equipped sure a to teams commercial We've As initiatives, help quickly are penetration remote best for up this adoption. support
of our the globe. disruptions the increased belief implementation hospital that these INTERCEPT, penetration offset slow will users than rate be this of across new by may more it existing While is with
posted we XXXX. results in Europe, QX to Turning strong
like hotspots, Towards and plasma kit to Italy COVID-XX an demand in demand the end pull plan franchise. plasma also increase increase some of March, above from contributed core platelet some for we our performance saw through Spain. This and market provided early our in
Kedrion, playing distribution In convalescent treat and Italy, distributor in COVID-XX the production a partner, leadership plasma role our patients. of to is coronavirus
Increased to slightly were proud to Spain and in be them offset are DSK. U.S French by We to this sales the ESS in conversion Italy partner ongoing able with effort. the
have impact the negative XXXX. the we currency revenue product mix As from we as rate, single double shifts to in the reported as France year-over-year contribute declines translation noted of to kit, in some foreign will before, in well
Germany. gears to Switching
deferrals. potential due to treatment. see Erling mitigate a efforts able Customers increasing INTERCEPT as PI, in COVID-XX institute order COVID-XX we their Recently, acquisition be related in endorsed to technology in and CPP PI starting peace Paul mechanism in to a CCP. offer to accelerate the donor as are had a to treaty. pathogen We Furthermore, part interest
franchise likely over a to is our time. have benefit Platelet positive This for
see region, encouraged uptick are we a While our we ramp our to in strength by what EMEA the across clarity. still to premature evolve. an will look it of Nevertheless, the are bit How business. encouraged is state adoption Germany, as we
challenge to in that chain Given operations and maintaining our up I the anticipated report demand proved happy integrity global top kits, priority. to security and QX. current am manufacturing, to end, a To that team continues for strong INTERCEPT the supply be
we have at the of with service have increased factories dynamically partners and supply levels to are our with measures maintain and manufacturing, that comply communication high to an our suppliers In ensure social chain, regulations. levels. ongoing distancing suppliers assessing we On implemented their local safety basis, throughout inventory our frequency can key
implications for volumes. inventory potential output assessing are and We production
ourselves that to belief and chain. maintain service strong to XXXX our our pandemic the positioned our expectations, have Given is a position is we demand decision. prudent supply entered is difficult successfully forecast customer in we that levels. growth What to inventory exactly be and proving certainly how meet won't It robust a high affect evolving increasing
and our to and it's teams customer to ensuring to created while operations gain chain pandemic third-party the in also access communication provided our grateful suppliers service these supply patients their for key and summary, to In times. has for partnership am commitment I INTERCEPT their unprecedented disruptions, opportunities.
of a COVID-XX truly greater on significance. concept the preparedness of As resonates result has and taken
Unfortunately, to if, now is as threats ensuring infectious Cerus the as optimize a is than disease disease are of to components hospital it hospitals this rise is the the can helping of and more safety. blood face and partners world. to important and centers of supply in to the We blood continue not be, today. global of feel availability in role Clearly, future positioned pandemic plays honored physician INTERCEPT is safe anticipation safety our partner new when major in grateful choice technology work rather be the COVID-XX is well but of the maintain across of matter outbreaks. ever. and a blood an important enabling and And blood center,
it that, for let a me over With Kevin detailed the to of review financials. turn
